Plus   Neg

Alexion Pharma Raises 2018 Guidance; Q1 Profit Beats Estimates - Quick Facts

Alexion Pharmaceuticals, Inc. (ALXN) announced the company now expects 2019 adjusted earnings per share in the range of $9.25 to $9.45, up from previous guidance range of $9.10 to $9.30. For 2019, the company projects total revenues of $4.675 billion to $4.750 billion, revised from prior outlook range of $4.625 billion to $4.700 billion. Analysts polled by Thomson Reuters expect the company to report profit per share of $9.31 on revenue of $4.75 billion, for fiscal year. Analysts' estimates typically exclude special items.

For the first-quarter, non-GAAP EPS was $2.39, compared to $1.68, a year ago. On average, 18 analysts polled by Thomson Reuters expected the company to report profit per share of $2.19 for the quarter.

First-quarter total net product sales were $1.14 billion, compared to $930.4 million, last year. Analysts expected revenue of $1.13 billion for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT